Acquista Criptovalute
Paga con
USD
USD
Buy & Sell
Hot
Supports Visa, Mastercard, SEPA & more
P2P
0 Fees
Flexible trading, zero fees
Gate Card
Use your crypto for payments worldwide
Mercati
Trading
Basic
Advanced
Futures
Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Opzioni
Hot
Trade European-style Vanilla Options
Conto unificato
Massimizza l'efficienza del tuo capitale
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Guadagna
Lancia
CandyDrop
Raccogli le caramelle per guadagnare airdrop
Launchpool
Staking rapido, guadagna potenziali nuovi token
HODLer Airdrop
Fai holding GT e ottieni enormi airdrop gratuitamente
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Investimento
Square
Square
Post, share, and explore crypto trends
Live
moments live
Live crypto market analysis
Chat
Chat with crypto traders
News
What is happening in crypto
flower_head
Altro
Promozioni
AI
Altro
TradFi
WCTC S8
Rewards
MET

Prezzo Metlife Inc

Closed
MET
$80,23
+$0,13(+0,16%)

*Data last updated: 2026-05-04 04:44 (UTC+8)

As of 2026-05-04 04:44, Metlife Inc (MET) is priced at $80,23, with a total market cap of $52,31B, a P/E ratio of 15,53, and a dividend yield of 2,82%. Today, the stock price fluctuated between $79,45 and $81,06. The current price is 0,98% above the day's low and 1,02% below the day's high, with a trading volume of 3,21M. Over the past 52 weeks, MET has traded between $67,60 to $81,06, and the current price is -1,02% away from the 52-week high.

MET Key Stats

Yesterday's Close$80,10
Market Cap$52,31B
Volume3,21M
P/E Ratio15,53
Dividend Yield (TTM)2,82%
Dividend Amount$0,59
Diluted EPS (TTM)5,08
Net Income (FY)$3,37B
Revenue (FY)$77,08B
Earnings Date2026-05-06
EPS Estimate2,25
Revenue Estimate$19,48B
Shares Outstanding653,11M
Beta (1Y)0.733
Ex-Dividend Date2026-05-12
Dividend Payment Date2026-06-09

About MET

MetLife, Inc., a financial services company, provides insurance, annuities, employee benefits, and asset management services worldwide. It operates through five segments: U.S.; Asia; Latin America; Europe, the Middle East and Africa; and MetLife Holdings. The company offers life, dental, group short-and long-term disability, individual disability, pet insurance, accidental death and dismemberment, vision, and accident and health coverages, as well as prepaid legal plans; administrative services-only arrangements to employers; and general and separate account, and synthetic guaranteed interest contracts, as well as private floating rate funding agreements. It also provides pension risk transfers, institutional income annuities, structured settlements, and capital markets investment products; and other products and services, such as life insurance products and funding agreements for funding postretirement benefits, as well as company, bank, or trust-owned life insurance used to finance nonqualified benefit programs for executives. In addition, it provides fixed, indexed-linked, and variable annuities; and pension products; regular savings products; whole and term life, endowments, universal and variable life, and group life products; longevity reinsurance solutions; credit insurance products; and protection against long-term health care services. MetLife, Inc. was founded in 1863 and is headquartered in New York, New York.
SectorFinancial Services
IndustryInsurance - Life
CEOMichel Abbas Khalaf
HeadquartersNew York City,NY,US
Official Websitehttps://www.metlife.com
Employees (FY)46,00K
Average Revenue (1Y)$1,67M
Net Income per Employee$73,45K

Ulteriori informazioni su Metlife Inc (MET)

Blogs

TWV0ZW9yYSAoTUVUKSBzdXBlcmEgaWwgNTAlIGluIHVuIHNvbG8gZ2lvcm5vOiByaXZhbHV0YXppb25lIGRlbCBwcm90b2NvbGxvIGRpIGxpcXVpZGl0w6AgZGkgU29sYW5hIGUgYW5hbGlzaSBkZWwgbWVjY2FuaXNtbyBETE1N

TWV0ZW9yYSAoTUVUKSDDqCBhdW1lbnRhdG8gZGkgb2x0cmUgaWwgNTAlIGluIHVuIHNvbG8gZ2lvcm5vLCBjb24gdW4gdm9sdW1lIGRpIHNjYW1iaSBuZWxsZSAyNCBvcmUgY2hlIGhhIHJhZ2dpdW50byBjaXJjYSAyNTkgbWlsaW9uaSBkaSBkb2xsYXJpLg==

2026-04-24

QW5hbGlzaSBkZWxsZSBwb2xpdGljaGUgU0VDIGRpIFBhdWwgQXRraW5zOiB1biBjYW1iaWFtZW50byBjb21wbGV0byBuZWwgcXVhZHJvIG5vcm1hdGl2byBzdGF0dW5pdGVuc2UgcGVyIGxhIGNvbmZvcm1pdMOgIGNyeXB0byAyMDI14oCTMjAyNg==

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

2026-04-21

T25kYXRhIGRpIGRlbGV2ZXJhZ2luZyBzdSBFVEg6IDMyMC4wMDAgRVRIIGEgcmlzY2hpbyBsaXF1aWRhemlvbmXigJRJbCBtZXJjYXRvIHNpIHN0YSBhdnZpY2luYW5kbyBhIHVuYSBzb2dsaWEgY3JpdGljYT8=

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

2026-02-06

Metlife Inc (MET) FAQ

What's the stock price of Metlife Inc (MET) today?

x
Metlife Inc (MET) is currently trading at $80,23, with a 24h change of +0,16%. The 52-week trading range is $67,60–$81,06.

What are the 52-week high and low prices for Metlife Inc (MET)?

x

What is the price-to-earnings (P/E) ratio of Metlife Inc (MET)? What does it indicate?

x

What is the market cap of Metlife Inc (MET)?

x

What is the most recent quarterly earnings per share (EPS) for Metlife Inc (MET)?

x

Should you buy or sell Metlife Inc (MET) now?

x

What factors can affect the stock price of Metlife Inc (MET)?

x

How to buy Metlife Inc (MET) stock?

x

Risk Warning

The stock market involves a high level of risk and price volatility. The value of your investment may increase or decrease, and you may not recover the full amount invested. Past performance is not a reliable indicator of future results. Before making any investment decisions, you should carefully assess your investment experience, financial situation, investment objectives, and risk tolerance, and conduct your own research. Where appropriate, consult an independent financial adviser.

Disclaimer

The content on this page is provided for informational purposes only and does not constitute investment advice, financial advice, or trading recommendations. Gate shall not be held liable for any loss or damage resulting from such financial decisions. Further, take note that Gate may not be able to provide full service in certain markets and jurisdictions, including but not limited to the United States of America, Canada, Iran, and Cuba. For more information on Restricted Locations, please refer to the User Agreement.

Other Trading Markets

MET
CFD
Fai trading

Metlife Inc (MET) Latest News

2026-05-02 09:30

MEV Robot Converts $0.22 to $696,000 via Meteora ANB Pool Exploit

According to SolanaFloor, an MEV robot exploited a vulnerability in Meteora's ANB pool to convert $0.22 USDC into $696,000 USDC in a single transaction. The ANB token fell 99% following the attack.

2026-05-02 04:51

Iran's Foreign Minister Says Country Willing to Engage in Diplomatic Talks with U.S. if Conditions Met

According to Iran's state media on May 2, Iran's Foreign Minister Abbas Araghchi stated that Tehran remains willing to engage in diplomatic dialogue with the United States if Washington abandons its "expansionist practices" and "threatening rhetoric."

2026-04-24 12:52

TradeStation Integrates Tradetron To Enable Automated Options Trading for Retail Traders

Gate News message, April 24 — TradeStation has integrated Tradetron, an automation platform, into its execution infrastructure through an API connection, enabling traders to build, test, and automate options strategies directly within the brokerage environment. The integration allows traders to construct multi-leg options strategies (strategies involving multiple positions or conditions) using a visual interface or pre-configured models, validate them through simulated trading, and automate execution once predefined criteria are met. John Bartleman, President and CEO of TradeStation Group, stated that the integration "provides a way to automate strategies, test them, and execute when conditions are met, while maintaining full control over strategy design and management." The move reflects a broader industry trend to democratize algorithmic trading by reducing the technical barriers traditionally required for automated execution. The integration comes amid elevated options trading activity; U.S.-listed options exceeded 15 billion contracts in 2025, marking multiple consecutive years of record volume. However, automated trading carries inherent risks, including execution errors, system outages, and potential deviations between backtested (historically simulated) performance and live market conditions, particularly during volatility. Traders must carefully design and monitor strategies to mitigate these risks.

2026-04-21 23:52

Four Tokens Now Available to New York Residents on Major CEX

Gate News message, April 21 — A major centralized exchange announced on April 22 that Meteora (MET), ArcBlock (ABT), Karrat (KARRAT), and World Mobile Token (WMTX) are now available to New York residents on its website and iOS and Android applications. Users can buy, sell, exchange, send, receive, or store these assets. The exchange holds a virtual currency business activity license issued by the New York State Department of Financial Services.

2026-04-02 02:41

Meteora：与 Drift 协议无任何交互，平台资金安全

Gate News 消息，4 月 2 日，Solana 流动性协议 Meteora 发布声明表示，Meteora 上所有资金均安全，平台所有功能及金库均未与 Drift 协议交互。

Hot Posts su Metlife Inc (MET)

NasirGw

NasirGw

7 minuti fa
$SKYAI – Sharp pump met with decisive rejection as momentum fades near local peak Trade Setup: Short $SKYAI • Entry Zone: 0.555 – 0.575 • Target 1: 0.525 • Target 2: 0.495 • Target 3: 0.460 • Stop Loss: 0.605 Price action exhibits a clear rejection following an abrupt upward spike, with momentum deteriorating near the localized top. The inability to sustain higher ground suggests buyer exhaustion is underway, positioning the asset for a corrective move toward lower support thresholds. Risk parameters are defined above the rejection zone at 0.605. Just click trade here 👇 ‌
SKYAI+16,76%
SKYAI+16,76%
0
1
0
0
SelfRugger

SelfRugger

19 minuti fa
5 Revealing Analyst Questions From Organon’s Q4 Earnings Call ============================================================= 5 Revealing Analyst Questions From Organon’s Q4 Earnings Call Jabin Bastian Thu, February 19, 2026 at 2:39 PM GMT+9 4 min read In this article: OGN +2.47% Organon's fourth quarter was met with a negative market reaction as operational challenges and shifting demand patterns weighed on results. Management pointed to continued pricing pressure, loss of exclusivity for key drugs like Atozet, and policy-related headwinds for Nexplanon in the U.S. as major drivers of the year-on-year revenue decline. Interim CEO Joe Morrissey emphasized that biosimilars, particularly Hadlima, and new product launches provided some offset, but cost containment efforts and product mix shifts could not fully mitigate gross margin compression. CFO Matthew Walsh described the gross margin decline as “primarily driven by pricing pressure and unfavorable product mix.” Is now the time to buy OGN? Find out in our full research report (it’s free). ### Organon (OGN) Q4 CY2025 Highlights: * **Revenue:** $1.51 billion vs analyst estimates of $1.51 billion (5.3% year-on-year decline, in line) * **Adjusted EPS:** $0.63 vs analyst expectations of $0.73 (13.3% miss) * **Adjusted EBITDA:** $383 million vs analyst estimates of $390.2 million (25.4% margin, 1.8% miss) * **EBITDA guidance for the upcoming financial year 2026** is $1.9 billion at the midpoint, in line with analyst expectations * **Operating Margin:** 14.4%, down from 18.1% in the same quarter last year * **Market Capitalization:** $1.94 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. ### Our Top 5 Analyst Questions From Organon’s Q4 Earnings Call * **Umer Raffat (Evercore ISI)** questioned the thoroughness of the company’s internal investigations into channel behavior issues. Board Chair Carrie Cox declined further comment, citing the sensitivity of ongoing matters. * **Michael Nedelcovych (TD Cowen)** asked about the impact of recent FDA biosimilar guidance and Nexplanon’s 2026 contribution. Interim CEO Joe Morrissey described changes as “incremental,” while CFO Matthew Walsh expects Nexplanon sales to remain roughly flat, balancing ex-U.S. growth with U.S. headwinds. * **Bhavin Patel (Bank of America)** pressed management on whether cost savings were offsetting underlying EBITDA declines and on the potential for Nexplanon REMS program friction. Walsh said savings were reinvested in growth, and R&D head Juan Camilo Ferreira expressed confidence in the recertification process limiting disruption. * **Ethan Brown (JPMorgan)** inquired about long-term margin trends and Nexplanon’s five-year label impact. Walsh stressed ongoing cost efficiency efforts and noted the largest reinsertion headwind would be in 2026, with less impact in subsequent years. * **Alexandra von Riesemann (Piper Sandler)** asked about pressure points in established brands and Vtama’s competitive positioning. Morrissey expects stabilization in established brands as respiratory risks diminish, while Walsh projected Vtama to grow in line with peers despite competitive pressures. Story Continues ### Catalysts in Upcoming Quarters Looking forward, the StockStory team will be tracking (1) execution of further cost reduction initiatives and their impact on margin stability, (2) volume and pricing trends for Nexplanon outside the U.S. as well as biosimilar adoption in new markets, and (3) stabilization in the established brands portfolio, especially in respiratory and fertility segments. Developments in the Nexplanon REMS program and debt reduction progress will also be important indicators. Organon currently trades at $7.41, down from $7.69 just before the earnings. In the wake of this quarter, is it a buy or sell? See for yourself in our full research report (it’s free for active Edge members). ### Our Favorite Stocks Right Now If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear. Don’t wait for the next volatility shock. Check out our Top 5 Growth Stocks for this month. This is a curated list of our _High Quality_ stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025). Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,754% five-year return). Find your next big winner with StockStory today. Terms and Privacy Policy Privacy Dashboard More Info
OGN+3,33%
0
0
0
0
SelfRugger

SelfRugger

26 minuti fa
The 5 Most Interesting Analyst Questions From Pinterest’s Q4 Earnings Call ========================================================================== The 5 Most Interesting Analyst Questions From Pinterest’s Q4 Earnings Call Jabin Bastian Thu, February 19, 2026 at 2:40 PM GMT+9 4 min read In this article: * StockStory Top Pick PINS +5.61% Pinterest’s fourth quarter was met with a significant negative reaction from the market, as revenue came in just below Wall Street’s expectations and guidance for the next quarter disappointed. Management attributed the gap to continued advertising pullbacks from large retail clients, who have been disproportionately impacted by tariffs and margin pressures. CEO Bill Ready described the company’s performance as not meeting its potential and highlighted the urgent need to diversify Pinterest’s advertiser base and accelerate its sales transformation. He specifically pointed to the company’s exposure to large retailers as a key reason why Pinterest felt industry-wide ad spending headwinds more acutely than some competitors. Is now the time to buy PINS? Find out in our full research report (it’s free). ### Pinterest (PINS) Q4 CY2025 Highlights: * **Revenue:** $1.32 billion vs analyst estimates of $1.33 billion (14.3% year-on-year growth, 0.8% miss) * **Adjusted EPS:** $0.67 vs analyst estimates of $0.67 (in line) * **Adjusted EBITDA:** $541.5 million vs analyst estimates of $547.1 million (41% margin, 1% miss) * **Revenue Guidance for Q1 CY2026** is $961 million at the midpoint, below analyst estimates of $981.8 million * **EBITDA guidance for Q1 CY2026** is $176 million at the midpoint, below analyst estimates of $205.4 million * **Operating Margin:** 22.8%, in line with the same quarter last year * **Monthly Active Users:** 619 million, up 66 million year on year * **Market Capitalization:** $10.89 billion While we enjoy listening to the management's commentary, our favorite part of earnings calls are the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention. ### Our Top 5 Analyst Questions From Pinterest’s Q4 Earnings Call * **Doug Anmuth (JPMorgan)** asked about the drivers of Q4 revenue softness and Q1 guidance. CFO Julia Donnelly explained that large retail advertisers pulled back on spend due to tariffs, and that these headwinds may persist into the next quarter. * **Ross Sandler (Barclays)** questioned the timing and impact of the salesforce transformation. CEO Bill Ready said near-term disruption is likely, with full benefits expected over several quarters as the new sales organization matures. * **Ken Gawrelski (Wells Fargo)** probed the need for further technology investment to broaden the advertiser base. Ready responded that AI-driven automation and third-party measurement integrations will be critical for attracting and retaining small business clients. * **Eric Sheridan (Goldman Sachs)** asked how Pinterest is positioned in a competitive digital advertising market increasingly shaped by AI and new entrants. Ready highlighted Pinterest’s unique visual-first platform and high commercial intent audience as key differentiators. * **Colin Alan Sebastian (Baird)** inquired about the factors influencing margin guidance. Donnelly detailed that deliberate AI investments and restructuring costs will be balanced by targeted operating expense reductions, resulting in roughly flat adjusted EBITDA margins excluding the impact of the TV Scientific acquisition. Story Continues ### Catalysts in Upcoming Quarters In the coming quarters, the StockStory team will be watching (1) evidence of successful expansion into mid-market, small business, and international advertisers, (2) the pace and impact of AI-powered product rollouts like Pinterest Assistant and Performance Plus enhancements, and (3) the speed and effectiveness of the new sales and go-to-market transformation. Progress on these fronts will be critical for closing the gap between user engagement and monetization. Pinterest currently trades at $16.40, down from $18.54 just before the earnings. Is there an opportunity in the stock?See for yourself in our full research report (it’s free for active Edge members). ### The Best Stocks for High-Quality Investors If your portfolio success hinges on just 4 stocks, your wealth is built on fragile ground. You have a small window to secure high-quality assets before the market widens and these prices disappear. Don’t wait for the next volatility shock. Check out our Top 6 Stocks for this week. This is a curated list of our _High Quality_ stocks that have generated a market-beating return of 244% over the last five years (as of June 30, 2025). Stocks that have made our list include now familiar names such as Nvidia (+1,326% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Kadant (+351% five-year return). Find your next big winner with StockStory today. Terms and Privacy Policy Privacy Dashboard More Info
0
0
0
0